Compare Stocks

Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded in 1989 and is headquartered in Iselin, NJ.

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.

Magna-Lab Inc. does not have significant operations. It intends to identify and merge with an operating company. Previously, the company was engaged in the research, development, and commercialization of disposable medical devices to enhance the effectiveness of magnetic resonance imaging in detection and diagnosis of heart disease. The company was founded in 1991 and is based in Plainview, New York. Magna-Lab Inc. is a subsidiary of Magna Acquisition LLC.

NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.